KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Current Assets (2016 - 2025)

Historic Current Assets for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Q3 2025 value amounting to $3.8 billion.

  • Jazz Pharmaceuticals' Current Assets fell 1445.29% to $3.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 billion, marking a year-over-year decrease of 1445.29%. This contributed to the annual value of $4.6 billion for FY2024, which is 3474.39% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Current Assets stood at $3.8 billion, which was down 1445.29% from $3.4 billion recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Current Assets registered a high of $4.6 billion during Q4 2024, and its lowest value of $2.5 billion during Q1 2022.
  • Its 5-year average for Current Assets is $3.2 billion, with a median of $3.2 billion in 2021.
  • Its Current Assets has fluctuated over the past 5 years, first skyrocketed by 10867.28% in 2021, then crashed by 2103.13% in 2022.
  • Over the past 5 years, Jazz Pharmaceuticals' Current Assets (Quarter) stood at $2.6 billion in 2021, then decreased by 0.2% to $2.6 billion in 2022, then soared by 31.82% to $3.4 billion in 2023, then surged by 34.74% to $4.6 billion in 2024, then fell by 18.86% to $3.8 billion in 2025.
  • Its last three reported values are $3.8 billion in Q3 2025, $3.4 billion for Q2 2025, and $4.1 billion during Q1 2025.